Two studies presented at EADV 2026 highlight misinformation and dermatologic complications linked to viral skincare routines on social media.
|Articles|August 3, 2010
Histogen names Dr. Sadick to advisory board
New York - Histogen, a regenerative-medicine company based in San Diego, has named Neil Sadick, M.D., to its scientific advisory board, PRWeb reports.
Advertisement
New York - Histogen, a regenerative-medicine company based in San Diego, has named Neil Sadick, M.D., to its scientific advisory board, PRWeb reports.
Dr. Sadick, founder of Sadick Dermatology in New York, is clinical professor of dermatology at Weill Cornell Medical College, New York, and president of the Cosmetic Surgery Foundation. He has written more than 500 peer-reviewed articles, written or edited more than 10 books on cosmetic surgery and other procedures, and contributed more than 75 medical-textbook chapters.
Advertisement
Related to this article
Can at-home dermarollers give the same results as in-office microneedling or is that just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.
Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of September.
Though convenient, SPF-infused cosmetics rarely deliver their labeled protection level in real-world use, underscoring the continued need for a dedicated broad-spectrum sunscreen as the foundation of any routine.
Genetic study links higher BMI to looking older, but causality stays unclear; Mendelian randomization flags shared signals and candidate genes needing validation.
Up to 91% of patients reached EASI-75 and up to 67% reached IGA 0/1 at week 152, with no new safety signals, according to Galderma's EADV 2026 data.
Phase 2 data presented at EADV 2026 showed daxdilimab significantly reduced disease activity and improved response rates in treatment-refractory DLE.
Presented as a late breaker at EADV 2026, mid-dose zumilokibart achieved EASI-75 in 65.9% of adults with atopic dermatitis vs 23.4% with placebo at week 16.
Advertisement
Advertisement
Trending on Dermatology Times
1
Late Breaking: Zumilokibart Meets Primary End Point in Phase 2 Atopic Dermatitis Trial
2
Daxdilimab Improves Disease Activity in Treatment-Refractory Discoid Lupus in Phase 2 Trial
3
Dupilumab Data at EADV 2026 Highlight Outcomes Across AD, CSU, and Prurigo Nodularis
4
Dermatology FDA and Pipeline Review: Q3 2026 Approvals and Readouts
5